NASDAQ$ARVN
Arvinas Inc. · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Arvinas reported a Q3 2025 net loss with significantly reduced R&D and G&A expenses and lower collaboration revenue due to concluded agreements.
Arvinas posted a net loss of $35.1 million for Q3 2025, reflecting decreased collaboration revenue and reduced operating expenses as the company transitions development responsibilities to partners.
- Q3 2025 revenue was $41.9 million, primarily from the Pfizer collaboration.
- GAAP R&D expenses dropped to $64.7 million, down from $86.9 million in Q3 2024.
- GAAP G&A expenses decreased sharply to $21.0 million from $75.8 million year-over-year.
- Arvinas ended the quarter with $787.6 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$41.9M
Revenue by segment
Arvinas · $30.3M total across 1 segment · Q3 2022
- Collaboration Revenue$30.3M+225.8%100.0%
Forward guidance
Arvinas expects its current cash position to fund operations into the second half of 2028 while it advances early-stage clinical and preclinical assets.
Tailwinds
- Strong cash position of $787.6 million to support pipeline development.
- Positive Phase 1 clinical data for ARV-102 in Parkinson’s disease patients.
- First preclinical data shared for ARV-027 showing disease-modifying potential in SBMA.
- ARV-806 demonstrated high potency and tumor regression in KRAS G12D models.
- FDA accepted NDA for vepdegestrant, with PDUFA date set for June 5, 2026.
Headwinds
- Q3 revenue fell sharply from prior year due to concluded Novartis and Bayer collaborations.
- ARV-393 Phase 1 trial has not yet reached effective exposure levels.
- Decreased cash from operations and stock repurchases reduced liquidity.
- Significant net loss of $35.1 million in Q3 despite cost cuts.
- Dependence on third-party commercialization plans for vepdegestrant may delay market entry.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro